Jessica Mellinger is a Gastroenterology physician affiliated with Henry Ford Health. OpenAlex indexes 136 publications with 4,601 citations (h-index 35); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
3rd Floor Taubman Ctr, Recp D
Ann Arbor, MI 481095362
Telephone
734-647-5944Registry record last updated 9 Jul 2015.
Clinical trials
- Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
Sponsor: Henry Ford Health System
Overall officialRecruitingNCT06269510 - Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Trial
Sponsor: University of Michigan
Overall officialCompletedNCT04473482
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk ASProgram year20256 payments$21,529openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim International GmbHProgram year20251 payment
- Novo Nordisk IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
44.7%Bile Acid19%Ursodiol100%Part D≥13 patientsRifamycin Antibacterial11.9%Xifaxan100%Part D<11 patients+ 2 more classes in this area
Cancer & immunology
31.5%Calcineurin inhibitor31.5%Tacrolimus61%Envarsus Xr22%Cyclosporine Modified16%Part D<11 patientsCardiovascular
13.8%Loop diuretic7.7%Furosemide100%Part D<11 patientsAldosterone antagonist (MRA)6.1%Spironolactone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2018–2026 per NIH RePORTER. The latest:
- Adaptive Interventions to Improve Alcohol Treatment Engagement among Alcohol-related Liver Disease Patients
Henry Ford Health + Michigan State University Health Sciences
FY2026$631,117R01AA030748 - 4/4: The INTEGRATE Study: Evaluating INTEGRATEd care to Improve Biopsychosocial Outcomes of Early Liver Transplant for Alcohol-Associated Liver Disease
Henry Ford Health + Michigan State University Health Sciences
FY2026$375,468R01AA030969 - Adaptive Interventions to Improve Alcohol Treatment Engagement among Alcohol-related Liver Disease Patients
Henry Ford Health + Michigan State University Health Sciences
FY2025$638,022R01AA030748
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease
Nature Reviews Gastroenterology & Hepatology
2025 - An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice
Clinical Gastroenterology and Hepatology
2025 - Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement
Nature Reviews Gastroenterology & Hepatology
2024 - Socio‐economic association of alcohol use disorder and cardiovascular and alcohol‐associated liver disease from 2010 to 2019
Alimentary Pharmacology & Therapeutics
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Philip, MD
Henry Ford Health
David Lanfear, MD
Henry Ford Health
Marvin Eng, MD
Henry Ford Health
Karthikeyan Ananthasubramaniam, MD
Henry Ford Health
Charles Rice, MD
The Rockefeller University
Edward Loftus, MD
Mayo Clinic Rochester
Naga Chalasani, MD
Indiana University School of Medicine
Bruce Sands, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”